Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents
复制标题
DOI：
10.1016/s0022-5347(05)65465-1
复制
发表时间：
2002-01-01
影响因子：
6.6
通讯作者：
Hsieh, JT
中科院分区：
文献类型：
--
作者：
Li, YM;Okegawa, T;Hsieh, JT
Purpose: Chemotherapy is often used as a primary therapy for metastatic cancer because it kills cells en masse. However, high doses of chemotherapeutic drugs can cause toxicity in nontarget organs. Gene therapy may provide a better alternative to chemotherapy because its targeting of specific genes may reduce the undesirable toxicity associated with chemotherapy. We evaluated whether the chemotherapeutic agent docetaxel or paclitaxel may be combined with gene therapy to create a new therapeutic regimen for metastatic androgen independent prostate cancer.Materials and Methods: The 2 androgen independent prostate cancer cell lines PC-3 and DU 145 were treated with docetaxel or paclitaxel. Three recombinant adenoviruses containing p21WAF-1/CIP1, p53 protein or beta -galactosidase complementary DNA under the control of cytomegalovirus promoter were used to determine transgene expression. They were evaluated by Western blot analysis, beta -galactosidase activity or in vitro growth assays. The [H-3] labeled El deleted adenovirus dl312 was used to determine adenovirus uptake into cells.Results: Docetaxel and paclitaxel enhanced adenovirus mediated transgene expression. Docetaxel appears to be a more potent growth inhibitor in vitro. Elevated transgene expression in virus infected cells induced by these 2 drugs was produced by increased cytomegalovirus promoter activity rather than increased virus uptake.Conclusions: The potential synergy of gene therapy with docetaxel and paclitaxel may be an important direction for future therapy for metastatic androgen independent prostate cancer.
